FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4380291517> ?p ?o ?g. }

• W4380291517 endingPage "28" @default.
• W4380291517 startingPage "15" @default.
• W4380291517 abstract "Aldo-keto reductase 1C3 (AKR1C3) has been postulated to be involved in androgen, progesterone, and estrogen metabolism. Aldo-keto reductase 1C3 inhibition has been proposed for treatment of endometriosis and polycystic ovary syndrome. Clinical biomarkers of target engagement, which can greatly facilitate drug development, have not yet been described for AKR1C3 inhibitors. Here, we analyzed pharmacodynamic data from a phase 1 study with a new selective AKR1C3 inhibitor, BAY1128688, to identify response biomarkers and assess effects on ovarian function.In a multiple-ascending-dose placebo-controlled study, 33 postmenopausal women received BAY1128688 (3, 30, or 90 mg once daily or 60 mg twice daily) or placebo for 14 days. Eighteen premenopausal women received 60 mg BAY1128688 once or twice daily for 28 days.We measured 17 serum steroids by liquid chromatography-tandem mass spectrometry, alongside analysis of pharmacokinetics, menstrual cyclicity, and safety parameters.In both study populations, we observed substantial, dose-dependent increases in circulating concentrations of the inactive androgen metabolite androsterone and minor increases in circulating etiocholanolone and dihydrotestosterone concentrations. In premenopausal women, androsterone concentrations increased 2.95-fold on average (95% confidence interval: 0.35-3.55) during once- or twice-daily treatment. Note, no concomitant changes in serum 17β-estradiol and progesterone were observed, and menstrual cyclicity and ovarian function were not altered by the treatment.Serum androsterone was identified as a robust response biomarker for AKR1C3 inhibitor treatment in women. Aldo-keto reductase 1C3 inhibitor administration for 4 weeks did not affect ovarian function.ClinicalTrials.gov Identifier: NCT02434640; EudraCT Number: 2014-005298-36." @default.
• W4380291517 created "2023-06-13" @default.
• W4380291517 creator A5001579910 @default.
• W4380291517 creator A5002836856 @default.
• W4380291517 creator A5003451608 @default.
• W4380291517 creator A5005660869 @default.
• W4380291517 creator A5010324154 @default.
• W4380291517 creator A5012769442 @default.
• W4380291517 creator A5019772332 @default.
• W4380291517 creator A5031304085 @default.
• W4380291517 creator A5031448884 @default.
• W4380291517 creator A5040630261 @default.
• W4380291517 creator A5055621937 @default.
• W4380291517 creator A5061531451 @default.
• W4380291517 creator A5068035236 @default.
• W4380291517 creator A5087286663 @default.
• W4380291517 date "2023-06-12" @default.
• W4380291517 modified "2023-10-18" @default.
• W4380291517 title "Novel aldo-keto reductase 1C3 inhibitor affects androgen metabolism but not ovarian function in healthy women: a phase 1 study" @default.
• W4380291517 cites W1142743052 @default.
• W4380291517 cites W1983461177 @default.
• W4380291517 cites W1988084110 @default.
• W4380291517 cites W1989115647 @default.
• W4380291517 cites W1996848378 @default.
• W4380291517 cites W1997065757 @default.
• W4380291517 cites W2004422115 @default.
• W4380291517 cites W2006788503 @default.
• W4380291517 cites W2026352933 @default.
• W4380291517 cites W2028633896 @default.
• W4380291517 cites W2030667838 @default.
• W4380291517 cites W2031230721 @default.
• W4380291517 cites W2032301907 @default.
• W4380291517 cites W2036334470 @default.
• W4380291517 cites W2065528753 @default.
• W4380291517 cites W2087523725 @default.
• W4380291517 cites W2098917345 @default.
• W4380291517 cites W2100176595 @default.
• W4380291517 cites W2130690545 @default.
• W4380291517 cites W2148450026 @default.
• W4380291517 cites W2480649858 @default.
• W4380291517 cites W2557976244 @default.
• W4380291517 cites W2558493999 @default.
• W4380291517 cites W2684997942 @default.
• W4380291517 cites W2809641829 @default.
• W4380291517 cites W2973660184 @default.
• W4380291517 cites W2980338581 @default.
• W4380291517 cites W2984626975 @default.
• W4380291517 cites W3010961934 @default.
• W4380291517 cites W4280564037 @default.
• W4380291517 doi "https://doi.org/10.1093/ejendo/lvad063" @default.
• W4380291517 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37306288" @default.
• W4380291517 hasPublicationYear "2023" @default.
• W4380291517 type Work @default.
• W4380291517 citedByCount "2" @default.
• W4380291517 countsByYear W43802915172023 @default.
• W4380291517 crossrefType "journal-article" @default.
• W4380291517 hasAuthorship W4380291517A5001579910 @default.
• W4380291517 hasAuthorship W4380291517A5002836856 @default.
• W4380291517 hasAuthorship W4380291517A5003451608 @default.
• W4380291517 hasAuthorship W4380291517A5005660869 @default.
• W4380291517 hasAuthorship W4380291517A5010324154 @default.
• W4380291517 hasAuthorship W4380291517A5012769442 @default.
• W4380291517 hasAuthorship W4380291517A5019772332 @default.
• W4380291517 hasAuthorship W4380291517A5031304085 @default.
• W4380291517 hasAuthorship W4380291517A5031448884 @default.
• W4380291517 hasAuthorship W4380291517A5040630261 @default.
• W4380291517 hasAuthorship W4380291517A5055621937 @default.
• W4380291517 hasAuthorship W4380291517A5061531451 @default.
• W4380291517 hasAuthorship W4380291517A5068035236 @default.
• W4380291517 hasAuthorship W4380291517A5087286663 @default.
• W4380291517 hasConcept C121608353 @default.
• W4380291517 hasConcept C126322002 @default.
• W4380291517 hasConcept C134018914 @default.
• W4380291517 hasConcept C142724271 @default.
• W4380291517 hasConcept C204787440 @default.
• W4380291517 hasConcept C27081682 @default.
• W4380291517 hasConcept C2776166826 @default.
• W4380291517 hasConcept C2776607906 @default.
• W4380291517 hasConcept C2777164284 @default.
• W4380291517 hasConcept C2777391703 @default.
• W4380291517 hasConcept C2777911890 @default.
• W4380291517 hasConcept C2778504769 @default.
• W4380291517 hasConcept C2779746161 @default.
• W4380291517 hasConcept C2779881493 @default.
• W4380291517 hasConcept C2780902042 @default.
• W4380291517 hasConcept C3018442814 @default.
• W4380291517 hasConcept C511355011 @default.
• W4380291517 hasConcept C530470458 @default.
• W4380291517 hasConcept C71315377 @default.
• W4380291517 hasConcept C71924100 @default.
• W4380291517 hasConcept C86803240 @default.
• W4380291517 hasConceptScore W4380291517C121608353 @default.
• W4380291517 hasConceptScore W4380291517C126322002 @default.
• W4380291517 hasConceptScore W4380291517C134018914 @default.
• W4380291517 hasConceptScore W4380291517C142724271 @default.
• W4380291517 hasConceptScore W4380291517C204787440 @default.
• W4380291517 hasConceptScore W4380291517C27081682 @default.
• W4380291517 hasConceptScore W4380291517C2776166826 @default.

• next